Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3785/j.issn.1008-9292.2020.03.06 http://scihub22266oqcxt.onion/10.3785/j.issn.1008-9292.2020.03.06 32391669!8800770!32391669     free     free     free Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538 Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538       Zhejiang+Da+Xue+Xue+Bao+Yi+Xue+Ban 2020 ; 49 (2): 227-231 Nephropedia Template TP {{tp|p=32391669|t=2020. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab |pdf=|usr=}}{{32391669}} gab.com Text Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab JO: Zhejiang Da Xue Xue Bao Yi Xue Ban http://www.kidney.de/pget.php?&tw=1&pmid=32391669 #FOAvip OBJECTIVE: To observe the clinical effect of plasma exchange and tocilizumab in treatment of patients with severe coronavirus disease 2019 (COVID-19). METHODS: Six patients with severe COVID-19 admitted in First Affiliated Hospital of Bengbu Medical College from January 25 to February 25, 2020. Three patients were treated with plasma exchange and three patients were treated with tocilizumab. The effect on excessive inflammatory reaction of plasma exchange and tocilizumab was observed. RESULTS: The C-reactive protein (CRP) and IL-6 levels were significantly decreased and the lymphocyte and prothrombin time were improved in 3 patients after treatment with plasma exchange; while inflammation level was not significantly decreased, and lymphocyte and prothrombin time did not improve in 3 patients treated with tocilizumab. CONCLUSIONS: For severe COVID-19 patients with strong inflammatory reaction, plasma exchange may be preferred. Twit Text FOAVip Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab ????Zhejiang Da Xue Xue Bao Yi Xue Ban http://www.kidney.de/pget.php?&tw=1&pmid=32391669 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32391669 #FOAvip English Wikipedia <ref>{{Cite pmid|32391669}}</ref> Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab #MMPMID32391669 Luo S; Yang L; Wang C; Liu C; Li D Zhejiang Da Xue Xue Bao Yi Xue Ban 2020[May]; 49 (2): 227-231 PMID32391669show ga OBJECTIVE: To observe the clinical effect of plasma exchange and tocilizumab in treatment of patients with severe coronavirus disease 2019 (COVID-19). METHODS: Six patients with severe COVID-19 admitted in First Affiliated Hospital of Bengbu Medical College from January 25 to February 25, 2020. Three patients were treated with plasma exchange and three patients were treated with tocilizumab. The effect on excessive inflammatory reaction of plasma exchange and tocilizumab was observed. RESULTS: The C-reactive protein (CRP) and IL-6 levels were significantly decreased and the lymphocyte and prothrombin time were improved in 3 patients after treatment with plasma exchange; while inflammation level was not significantly decreased, and lymphocyte and prothrombin time did not improve in 3 patients treated with tocilizumab. CONCLUSIONS: For severe COVID-19 patients with strong inflammatory reaction, plasma exchange may be preferred. |*Antibodies, Monoclonal, Humanized/administration & dosage[MESH] |*Coronavirus Infections/blood/immunology/therapy[MESH] |*Pandemics[MESH] |*Plasma Exchange/standards[MESH] |*Pneumonia, Viral/blood/immunology/therapy[MESH] |Betacoronavirus/isolation & purification[MESH] |COVID-19[MESH] |Cytokine Release Syndrome/therapy[MESH] |Humans[MESH] |Prothrombin Time[MESH] |SARS-CoV-2[MESH] Clinical observation of 6 severe COVID-19 patients treated with plasm(epmc).pdf DeepDyve Pubget Overpricing